Eli Lilly & Co. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
1.07 B |
Public Float |
968.44 M |
Eli Lilly & Co. | |
Stock Exchange | Mexican Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
1.09 B |
Public Float |
968.44 M |
Eli Lilly & Co. | |
Stock Exchange | New York Stock Exchange |
EPS |
$2.5 |
Market Cap |
$109.53 B |
Shares Outstanding |
970.83 M |
Public Float |
916.04 M |
Eli Lilly & Co. | |
Stock Exchange | Euronext Paris |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
1.07 B |
Public Float |
968.44 M |
Eli Lilly & Co. | |
Stock Exchange | SIX Swiss Exchange |
EPS |
CHF2.48 |
Market Cap |
CHF106.79 B |
Shares Outstanding |
1.07 B |
Public Float |
968.44 M |
Address |
Lilly Corporate Center Indianapolis Indiana 46285 United States |
Employees | - |
Website | http://www.lilly.com |
Updated | 07/08/2019 |
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. |